A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ONCE-DAILY INHALED MOLGRAMOSTIM NEBULIZER SOLUTION IN ADULT SUBJECTS WITH AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)
- Registry ID
- SAV006-05
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- SAVARA INC.
- Start date
- 2024-02-19
- Last update
- 2020-12-30
Conditions
- AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS
- AUTOIMMUNE DISEASE
Related clinical trials
- A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORAL BREPOCITINIB IN ADULTS WITH LICHEN PLANOPILARIS
- A PHASE 1 OPEN-LABEL, MULTIREGIONAL, MULTICENTER, BASKET STUDY EVALUATING THE SAFETY AND EFFICACY OF KITE-363, AN AUTOLOGOUS ANTI-CD19/CD20 CAR T-CELL THERAPY IN PARTICIPANTS WITH REFRACTORY AUTOIMMUNE DISEASES
- A PHASE 1 STUDY EVALUATING THE SAFETY AND PRELIMINARY EFFICACY OF ALLO-
329, A DUAL ANTI-CD19 / ANTI-CD70 ALLOGENEIC CAR T CELL PRODUCT IN
AUTOIMMUNE DISEASE (RESOLUTION)
- A RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO DEMONSTRATE THE COMPARABILITY
OF PHARMACOKINETICS OF SUBCUTANEOUS IANALUMAB BETWEEN 2ML AUTOINJECTOR/2ML PRE-FILLED SYRINGE WITH 1 ML PRE-FILLED SYRINGE IN ADULT
PARTICIPANTS WITH AUTOIMMUNE DISEASE
- PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES (RAINBOW TRIAL)
- A THREE-PERIOD MULTICENTER STUDY, WITH A RANDOMIZED WITHDRAWAL, DOUBLE-BLINDED, PLACEBO-CONTROLLED DESIGN TO EVALUATE THE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF MAS825 IN PATIENTS WITH MONOGENIC IL-18 DRIVEN AUTOINFLAMMATORY DISEASES, INCLUDING NLRC4-GOF, XIAP DEFICIENCY, OR CDC42 MUTATIONS
View on source registry